Three-Step Synthesis of the Antiepileptic Drug Candidate Pynegabine.
Molecules
; 28(13)2023 Jun 21.
Article
en En
| MEDLINE
| ID: mdl-37446549
ABSTRACT
Pynegabine, an antiepileptic drug candidate in phase I clinical trials, is a structural analog of the marketed drug retigabine with improved chemical stability, strong efficacy, and a better safety margin. The reported shortest synthetic route for pynegabine contains six steps and involves the manipulation of highly toxic methyl chloroformate and dangerous hydrogen gas. To improve the feasibility of drug production, we developed a concise, three-step process using unconventional methoxycarbonylation and highly efficient Buchwald-Hartwig cross coupling. The new synthetic route generated pynegabine at the decagram scale without column chromatographic purification and avoided the dangerous manipulation of hazardous reagents.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Hidrógeno
/
Anticonvulsivantes
Idioma:
En
Revista:
Molecules
Asunto de la revista:
BIOLOGIA
Año:
2023
Tipo del documento:
Article